公司新闻 - Apellis Pharmaceuticals, Inc.宣布将参加三月份的投资者会议[1] - 公司开发针对一些严重疾病的治疗方案，包括首个治疗地理性萎缩的疗法[2] 联系方式 - 投资者联系方式为Meredith Kaya，邮箱为meredith.kaya@apellis.com，电话为617.599.8178[3]

Investors are always looking for stocks that are poised to beat at earnings season and Apellis Pharmaceuticals, Inc. (APLS) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Apellis is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pre ...

股票评级 - Apellis Pharmaceuticals, Inc. (APLS) 最近被升级为 Zacks Rank 2 (Buy) [1] - Zacks评级系统主要跟踪卖方分析师对公司股票的盈利预期，这对股价有着强大的影响力 [2] - 过去三个月，分析师们一直在稳步提高对Apellis Pharmaceuticals, Inc.的盈利预期，Zacks共识预期增长了38.6% [10] 盈利预期 - Apellis Pharmaceuticals, Inc.预计2023年度每股亏损为-4.41美元，同比增长28.3% [9] 股价展望 - Zacks评级升级意味着对Apellis Pharmaceuticals, Inc.盈利前景的积极评价，可能对其股价产生有利影响 [4] - Apellis Pharmaceuticals, Inc.的Zacks Rank 2将其定位在Zacks覆盖股票的前20%，意味着股价可能在短期内上涨 [13]

Apellis Pharmaceuticals, Inc. - Apellis Pharmaceuticals, Inc. 是医疗组中的一家公司，目前在 Zacks Sector Rank 中排名第5位[2] - Apellis Pharmaceuticals, Inc. 目前的 Zacks Rank 为 2 (Buy)，过去90天的 Zacks Consensus Estimate 预测公司全年收益增长了38.6%[3] - Apellis Pharmaceuticals, Inc. 在今年迄今为止的表现比医疗行业平均表现更好，股价上涨了10.5%[4] Arcutis Biotherapeutics, Inc. - Arcutis Biotherapeutics, Inc. 是另一家医疗股，今年迄今为止的回报率为113.6%[5] - Arcutis Biotherapeutics, Inc. 目前的 Zacks Rank 为 2 (Buy)，过去三个月的一致 EPS 预测为今年增长了0.2%[6] - Apellis Pharmaceuticals, Inc. 和 Arcutis Biotherapeutics, Inc. 都属于医疗 - 生物医学和遗传学行业，该行业今年迄今平均下跌了1.3%[7] 投资建议 - 投资者可能需要密切关注 Apellis Pharmaceuticals, Inc. 和 Arcutis Biotherapeutics, Inc.，因为它们试图继续保持良好的表现[8]

公司业绩 - Apellis Pharmaceuticals, Inc. (APLS) 预计在2023年12月报告的季度业绩中，盈利将同比增长，收入也将增加[1] - 分析师们对公司的盈利前景持悲观态度，最准确的估计低于Zacks的共识估计，导致盈利预期偏差为-14.84%[12] - 过去四个季度中，Apellis Pharmaceuticals, Inc. 两次超过共识EPS估计，但上一季度的盈利预期却低于实际值[15] - Zacks Earnings ESP 模型显示，正的Earnings ESP是盈利超预期的强有力预测因素，尤其是与Zacks Rank 1 (Strong Buy), 2 (Buy) 或 3 (Hold)结合时[10]

WALTHAM, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company approved the grant of equity awards to 4 new employees with a grant date of February 1, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5 ...

Apellis Pharmaceuticals (APLS) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has voted against the approval of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).The negative opinion of the CHMP was expected as the company previously announced a negative trend vote on the marketing authorization application (MAA) for pegcetacoplan following an oral explanation meeting in ...

Apellis Pharmaceuticals, Inc.申请被否定 - 欧洲药品管理局(CHMP)对Apellis Pharmaceuticals, Inc.的申请做出了否定意见[1] Pegcetacoplan治疗年龄相关性黄斑变性(GA)的申请 - Pegcetacoplan治疗年龄相关性黄斑变性(GA)的申请基于OAKS和DERBY两项第三阶段研究结果[2] GA疾病情况 - GA是一种进行性不可逆的视力丧失形式，欧洲有超过250万人患有该疾病[3]

One stock that might be an intriguing choice for investors right now is Apellis Pharmaceuticals, Inc. (APLS) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably ...

Apellis Pharmaceuticals (APLS) reported net product sales of approximately $138 million in the United States for the fourth quarter of 2023, up significantly year over year. The company generates product revenues from the sale of its two marketed drugs, Empaveli (pegcetacoplan) and Syfovre (pegcetacoplan injection). Its top line also comprises of licensing and other revenues.The 39% sequential increase in product revenues (from $99.2 million) was driven by strong Syfovre sales. Syfovre recorded sales of $11 ...